PCASE11 SYNAGIS 2005–2006 SEASON

SYNAGIS® (PALIVIZUMAB) for Intramuscular Administration

DESCRIPTION: Synagis® (palivizumab) is a humanized monoclonal antibody (IgG1κ ) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variab...

Palivizumab (synagis): counting "costs" and values.

The continuing reports, letters, and pharmacoeconomic analyses concerning the use of expensive respiratory syncytial virus (RSV) prophylaxis regimens for neonatal intensive care unit (NICU) graduates mark what appears to be a shift in decisional processes for clinicians.1–3 The consideration of cost, although not new in medical or pediatric decision-making, must be approached with care as decis...

An In-Home Synagis Program for RSV Prevention in High-Risk Infants

RESULTS: Compared with published reports of office, outpatient, or clinicbased RSV prophylaxis with palivizumab, in-home prophylaxis demonstrated low incidence of total hospitalizations (11.4% versus 14.4%) and RSV-related hospitalizations (2.3% versus 4.8%). Less than 10% of patients required an ED visit and only 1% of those were related to RSV illness. Only one of the hospitalized infants req...

OFISA Newsletter SEASON

A Cholera Season

In the April number of this Gazette reference was made to the measures which had been adopted to deal with cholera and prevent it, if possible, taking on an epidemic form in, the villages adjacent to the labour forces and amongst the coolies engaged upon the construction of the bridge across the Lower. Granges. Our chief cholera season coincides with the greater part of the earthwork coolies' w...